glp 1 agonist long term side effects glp-1 long-term cancer Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds PDF) Exploring the Side Effects
Description
As such, GIP/GLP receptor co-agonists perhaps represent more suitable candidates in the treatment of neurodegenerative conditions
The recommendation is based on a trial comparing semaglutide with placebo in people with overweight/obesity with CVD but no diabetes (Lincoff et al, 2023)
Both formulations are administered as once-weekly SC injections due to the long half-life of Semaglutide (approximately one week)
Front Endocrinol (Lausanne) (2021) 12:721135
doi: 10.1523/JNEUROSCI.6144-08.2009
